Furthermore, a phase 3 study (NCT04427072) investigating capmatinib versus docetaxel in previously treated patients with MET exon 14 skipping NSCLC is still ongoing, while two clinical trials evaluating the safety and efficacy of capmatinib in combination with immunotherapeutic agents (spartalizumab and pembrolizumab) were recently terminated due to lack of tolerability observed in the combination treatment group when compared to data from single agent studies (NCT04323436, NCT04139317). The gene discussed is MET; the disease is non-small cell lung carcinoma.